Vol 95, No 7 (2023)

Cover Page

Full Issue

Editorial

Positron emission tomography in cardiological practice

Sergienko V.B., Ansheles A.A.

Abstract

The utility of positron emission tomography in cardiology currently goes beyond the ischemic heart disease and covers an increasingly wider range of non-coronary pathology, which requires timely expert diagnostics, including chronic heart disease of any etiology, valvular and electrophysiology disorders, cardiooncology. Authors emphasize the importance of the development of positron emission tomography technologies in the Russian Federation. This includes the development and implementation of new radiopharmaceuticals for the diagnosis of pathological processes of the cardiovascular system, systemic and local inflammation, including atherosclerosis, impaired perfusion and myocardial metabolism, and also for solving specific diagnostic tasks in comorbid pathology.

Terapevticheskii arkhiv. 2023;95(7):531-536
pages 531-536 views

Original articles

Features of the course and adverse events risk of coronavirus infection COVID-19 in hematological diseases (data from the CHRONOS19 register for the Primorsky Territory, intermediate stage)

Talko A.V., Nevzorova V.A., Dubov V.S., Muzychenko N.S., Gurbanov E.R., Dubov S.K., Beniova S.N., Simakova A.I.

Abstract

Aim. To assess the characteristics of the course of coronavirus infection COVID-19 and to determine the risk factors for adverse events in patients of the regional hematological center.

Materials and methods. As part of an observational prospective cohort study, data from 144 medical records of patients in Primorsky Krai with hematological diseases and COVID-19 were analyzed. The data of the developed standardized questionnaire of the CHRONOS19 study were used. The primary endpoint (adverse outcome) was a composite point that included mortality from any cause during the observation period, development of acute respiratory distress syndrome, hospitalization in the intensive care unit, and the need for mechanical ventilation.

Results. A study of the features of the course of COVID-19 in hematological patients showed an increase in the number of adverse events in patients with neoplastic blood diseases, especially in chronic lymphoproliferative diseases and acute myeloid leukemia. Significant predictors of an unfavorable course of COVID-19 include a refractory/recurrent variant of the course of a blood tumor, glucocorticoid therapy as part of the protocol for the treatment of the underlying disease, stage 3–4 lung damage according to computerised tomography scans at the onset of COVID-19, and the presence of diabetes mellitus.

Conclusion. Predictors of an unfavorable course of COVID-19 in hematological patients have been identified. Hematological patients in the context of the COVID-19 pandemic require a coordinated interdisciplinary approach involving hematologists and therapists, careful monitoring of clinical and laboratory parameters to reduce the risk of adverse events.

Terapevticheskii arkhiv. 2023;95(7):537-542
pages 537-542 views

The survival prediction of hospitalized patients with COVID-19: the role of chitotriosidase level in peripheral blood

Schelkanovtseva E.S., Isaev G.O., Mironova O.Y., Balakhonov A.A., Skvortsov A.V., Nagornov I.O., Suvorov A.Y., Fomin V.V., Panferov A.S.

Abstract

Aim. To assess the relationship between plasma chitotiosidase (CHIT) level and mortality in hospitalized patients with COVID-19.

Materials and methods. 347 hospitalized patients with COVID-19 were enrolled in our single-center cohort prospective observational study. On the first day of hospitalization the patients were assessed by the level of CHIT in the venosus blood to addition to default laboratory examinations. The primary endpoint was all-cause death. The survival after hospital discharge were assessed via phone calls on 90 and 180 days since inclusion to the study (NCT04752085).

Results. Our study included 347 patients. The first symptoms appeared in 7 days [5; 7] before hospitalization; 283 (84.3%) patients had less than 50% of the involvement of the lung tissue to the inflammation process (CT 0–2); 36 (10.4%) patients had died since the start of our investigation; 30 (83.3%) of them died during hospitalization, others -no later than 60 days; 68 (19%) people didn’t answer during phone call. The survivor's activity of the enzyme in the deceased was significantly lower in compare to deceased patients (90.5 [40.2; 178.0] nmol/h/mL vs 180.0 [77.2; 393.2] nmol/h/mL; p=0.001). Survivor of the patients with a higher level of the activity of the CHIT (more than 171 nmol/h/mL) was statically significantly lower.

Conclusion. Rising of the CHIT's activity more than 171 nmol/h/mL might be an early independent predictor of the bad prognosis of the patients, who were hospitalized with COVID-19 infection.

Terapevticheskii arkhiv. 2023;95(7):543-547
pages 543-547 views

Association between cardio-ankle vascular index and markers of thrombosis in hospitalized patients COVID-19

Podzolkov V.I., Bragina A.E., Tarzimanova A.I., Ogibenina E.S., Shvedov I.I., Ivannikov A.A., Megeneishvili N.К., Sutulova A.V.

Abstract

Aim. To evaluate the relationship between the cardio-ankle vascular index (CAVI) and the marker of procoagulant state – D-dimer in hospitalized patients with coronavirus disease 2019 (COVID-19).

Materials and methods. This cross-sectional study involved adult patients admitted to the University hospital with clinically diagnosed or laboratory-confirmed COVID-19. We compared groups of patients with normal and elevated CAVI. Univariate and multivariate logistic regression analyses were performed to assess the association between risk factors and elevated D-dimer levels; odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated to determine the strength of association. A p<0.05 was considered statistically significant.

Results. The study included 152 patients [64 (42.1%) men and 88 (57.9%) women], mean age 59.10±12.74 years. 45 (29.6%) had elevated CAVI. Patients with elevated CAVI were older, had more comorbid diseases, a higher Charlson comorbidity index and D-dimer levels. Age, the comorbidity index, and CAVI above 9.5 were associated with elevated D-dimer levels in patients with COVID-19. In a multivariate logistic regression, CAVI above 9.5 was an independent predictor of increased D-dimer in patients with COVID-19 (OR 2.513, 95% CI 1.050–6.012; p=0.038).

Conclusion. In this study, for the first time, the association between a vascular stiffness marker, elevated CAVI, and increased D-dimer levels in COVID-19 patients was shown. This relationship may be a consequence of endothelial dysfunction and can be used as an additional marker of coagulopathy developing as part of COVID-19.

Terapevticheskii arkhiv. 2023;95(7):548-553
pages 548-553 views

Adherence to treatment of hematological malignancies patients with anxiety and depression

Vybornykh D.E., Moiseeva T.N., Gemdzhian E.G., Gaponova T.V., Esina L.V., Kolgaeva E.I., Novikova D.V.

Abstract

Aim. To establish the features of the influence of anxiety and depressive disorders on treatment adherence, as well as to clarify the factors associated with it in hematologic malignancies patients.

Materials and methods. The study included 117 patients: 51 men and 66 women, aged 19 to 67 years, with Hodgkin's lymphoma – 88, acute lymphoblastic leukemia – 16 and aplastic anemia – 13 patients. Patients were examined by psychiatrist using the Brief Psychiatric Rating Scale, as well as some psychometric methods.

Results. Anxiety-depressive spectrum disorders were detected in 36 (40.9%) patients with Hodgkin's lymphoma and 8 (50%) with acute lymphoblastic leukemia, in the aplastic anemia group there were three (23.1%) of such patients. It was found that the average adherence to treatment was in 2/3 of patients, low and high – in the remaining 1/3 of patients. With medium and low adherence to treatment, the risk of adverse events increases by an average of 1.7 times. The adherence to treatment it is significantly higher in patients older than 45 years. Signs of depression that negatively correlated with adherence to treatment were pessimism and disruption of social ties. Adherence to treatment significantly positively correlates with the following types of attitudes towards the disease: anosognosic, hypochondriac and egocentric, and significantly negatively correlates with the following types of attitudes towards the disease: anxious, melancholic and dysphoric.

Conclusion. Anxiety/depressive disorders contribute to reduced adherence of hematologic malignancies patients to treatment. Their correction and increased adherence should be carried out jointly by hematologists and mental health professionals.

Terapevticheskii arkhiv. 2023;95(7):554-559
pages 554-559 views

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure

Vitsenya M.V., Potekhina A.V., Gavryushina S.V., Ibragimova N.M., Stukalova O.V., Masenko V.P., Sharf T.V., Ageev F.T.

Abstract

Aim. To evaluate the effect of Sacubitril/Valsartan (S/V) on the functional status, systolic and diastolic function of the left ventricle (LV), tolerability of therapy and to determine predictors of its effectiveness in patients with cancer therapy-related heart failure (СTRHF).

Materials and methods. Forty patients 58 [46; 65.5] years of age with HF associated with anthracycline-containing cancer therapy were enrolled. Clinical examination, echocardiography, and assessment of potassium and creatinine levels were performed at baseline and after 6 months of S/V therapy.

Results. NYHA functional class (FC) improvement was observed in 22 (64.7%) patients. Radiation therapy (RT) decreased (OR 0.091; 95% CI 0.01–0.83; p=0.03) while baseline low LV EF increased (OR 9.0; 95% CI 1.78–45.33; p=0.008) the odds of FC improvement. LV EF increased from 37.3 [30; 42.5] % to 45 [38; 48] % (p<0.0001) and exceeded 50% in 7 (20.6%) patients. The odds of LV EF recovery increased when S/V therapy was initiated ≤1 year after anthracycline therapy (OR 10.67; 95% CI 1.57–72.67; p=0.0016) and decreased in patients with the history of RT (OR 0.14; 95% CI 0.02–0.89; p=0.0037) and in patients over 58 years (OR 0.07; 95% CI 0.01–0.68; p=0.022). LV diastolic function improvement included E/e’ descent from 13.6 [10; 18.3] to 8.9 [6.9; 13.7] (p=0.0005), and decrease in diastolic dysfunction grade in 18 (45%) patients (p=0.0001). No significant change in serum potassium (4.45 [4.2; 4.8] versus 4.5 [4.3; 4.8]; p=0.5) and creatinine (75.4 [67.6; 85.1] versus 75.5 [68.2; 98.3]; p=0.08) levels were observed.

Conclusion. S/V therapy is associated with improvement of EF, systolic and diastolic LV function, demonstrates a favorable tolerability profile in patients with СTRHF. Lack of RT and low baseline LV EF increased the odds of LV EF improvement; lack of RT, early (≤1 year) start of treatment after discontinuation of anthracycline therapy, and age <58 years increased the odds of LV EF recovery.

Terapevticheskii arkhiv. 2023;95(7):560-567
pages 560-567 views

Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study)

Fomina D.S., Fedosenko S.V., Bobrikova E.N., Chernov A.A., Mukhina O.A., Lebedkina M.S., Karaulov A.V., Nurtazina A.Y., Lysenko M.A.

Abstract

Background. Dupilumab, a fully human monoclonal antibody directed against the common α-subunit of interleukin (IL)-4 receptors and blocking signaling from both IL-4 and IL-13, may be recommended for the treatment of moderate to severe atopic dermatitis (AD) and bronchial asthma (BA).

Aim. To perform a comparative assessment of the effectiveness of maintenance therapy with dupilumab in patients with severe BA as the main indication for genetically engineered biological drugs and in patients with severe asthma with concomitant severe AD as the indication for targeted therapy.

Materials and methods. A 6-month retrospective comparative study was performed at the specialized reference center for allergology and immunology. The study included 115 adult patients of both sexes treated with dupilumab for uncontrolled severe asthma as the main indication for targeted therapy (BA group; n=65) or for a combination of severe uncontrolled asthma and severe AD (BAAD; n=50). Dupilumab was administered subcutaneously for 6 months. The first dose was 600 mg once and then 300 mg Q2W. Evaluation of the effectiveness of dupilumab therapy at 6 months of treatment in both groups included achieving asthma control (ACT, ACQ5), improving pulmonary function test, reducing the risk of exacerbations and the need for systemic glucocorticosteroids (SGCS), improving quality of life (AQLQ), change of biomarkers (FeNO, eosinophil count) and the course of comorbid diseases, including improvement in the AD (SCORAD, EASI) and rhinosinusitis polyposa (SNOT-22).

Results and conclusion. During dupilumab therapy, in a significant proportion of patients, regardless of the presence or absence of other T2-associated diseases (e.g., AD or rhinosinusitis polyposa), an improvement in asthma was demonstrated as early as in the first 6 months of treatment with dupilumab in all recommended domains for assessing the response to targeted therapy: improving asthma control and respiratory function, reducing the frequency of moderate and severe exacerbations associated with the use of SGCS and/or hospitalization, a positive effect on the quality of life and the comorbid diseases, as well as a cumulative reduction in the need for SGCS.

Terapevticheskii arkhiv. 2023;95(7):568-573
pages 568-573 views

Clinical notes

Right ventricle free wall rupture during transcatheter occluder implantation in a patient with postinfarction rupture of the interventricular septum and COVID-19-associated myocarditis. Case report

Pevzner D.V., Sukhinina T.S., Anufriev E.N., Kostritca N.S., Avetisyan E.A., Shitov V.N., Kurilina E.V., Osiev A.G., Merkulov E.V., Tereshchenko A.S., Boytsov S.A.

Abstract

Intraventricular septum rupture is a rare mechanic complication of myocardial infarction associated with high mortality. This case describes STEMI in recovered patient after COVID 19 associated pneumonia, which was complicated by ventricular septum rupture followed by cardiogenic shock. It was managed by percutaneous occluder implantation. The procedure was complicated by right ventricular wall rupture. Postmortem examination of myocardium showed the signs of inflammation infiltrate and myocyte necrosis, according to histopathological Dallas criteria diagnosis of COVID-19 associated myocarditis was established. The COVID-19 pandemic has contributed to increasing cardiovascular mortality. This is typically attributed to diminishing resources for timely and appropriate medical care, and patients’ late presentations for fear of contracting the infection. Cardiovascular complication of COVID-19 may be another contributing factor. Further research is needed to improve our understanding of the mechanisms and long-term sequelae of myocardium damage in COVID-19, to optimize treatment strategy and subsequent follow-up in such patients.

Terapevticheskii arkhiv. 2023;95(7):574-579
pages 574-579 views

Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report

Mozdon M.A., Ponomarev R.V., Tsvetaeva N.V., Shabrin A.V., Ermachenkova E.I., Larichev S.E., Lukina E.A.

Abstract

Rendu–Osler–Weber disease or hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease. It is characterized by vascular dysplasia with the formation of telangiectasias on the skin, mucous membranes of the respiratory and digestive tracts, arteriovenous malformations (AVMs) in the internal organs, which is manifested by bleeding. Diagnosis is based on Curacao criteria: recurrent and spontaneous nosebleeds, multiple telangiectases on the characteristic localizations, AVMs in one or more of the internal organs, a family history of HHT (i.e. first-degree relative who meets these same criteria for definite HHT). Therapy is aimed at preventing and stopping gastrointestinal, nosebleeds, correction of iron deficiency anemia. A promising method of therapy is the use of angiogenesis inhibitors, in particular bevacizumab. The article presents a description of a clinical case of HHT in a 49-year-old woman with telangiectisia on the mucous membrane of the tongue, gastrointestinal tract and liver AVMs.

Terapevticheskii arkhiv. 2023;95(7):580-585
pages 580-585 views

Reviews

Diseases of the gastrointestinal tract in the context of COVID-19 infection: present and future challenges: A review

Maev I.V., Osadchuk M.A.

Abstract

A significant prevalence of gastrointestinal symptoms in SARS-CoV-2 infection is also associated with its fecal-oral transmission, which leads to a progressive increase in the number of patients with diseases of the esophagus, stomach and intestines. In addition, intestinal infections caused by SARS-CoV-2 may be one of the main causes of functional long-term stress-related gastrointestinal disorders, united in the concept of post-COVID syndrome.

Terapevticheskii arkhiv. 2023;95(7):586-590
pages 586-590 views

Vaping and vaping-associated lung injury: A review

Podzolkov V.I., Vetluzhskaya M.V., Abramova A.A., Ishina T.I., Garifullina K.I.

Abstract

Vaping, i.e. the use of electronic nicotine/other substances delivery systems, increases a risk of vaping-associated lung injury. The review describes clinical manifestation, methods of diagnosis and diagnostic criteria, treatment of patients with this disease as well as risk stratification of vapers and approaches to their management based on Worchester classification and clinical guidance. The pathogenetic mechanisms of vaping-associated lung injury have been analyzed.

Terapevticheskii arkhiv. 2023;95(7):591-596
pages 591-596 views

History of medicine

On the formation of Soviet haematology as an independent scientific clinical discipline and medical profession

Borodulin V.I., Banzelyuk E.N., Pashkov K.A., Topolyanskiy A.V.

Abstract

On the basis of a critical analysis of sources and the use of comparative historical research method, the authors reveal the fundamental role of Academician of the USSR Academy of Sciences I.A. Kassirsky in the formation of haematology as an independent clinical discipline in the USSR and put forward the thesis of the decisive importance in this process of the unified haematological school of A.N. Kryukov – I.A. Kassirsky.

Terapevticheskii arkhiv. 2023;95(7):597-601
pages 597-601 views

Dr. Sergey P. Botkin's case sheet

Dvoretsky L.I.

Abstract

The article presents and discusses Botkin's case sheet focused on his cardiac disease. Analysis of the clinical symptoms and course of the disease provides an opportunity from the standpoint of modern clinical cardiology to characterize the features of Botkin's disease course at all stages of its cardiological continuum and assess the diagnostic capabilities and managing approach to such patients. The comorbidity of ischemic heart disease and gallstone disease in the case of Dr. Sergey P. Botkin, a Russian general practitioner, pathologist, physiologist, and one of the founders of scientific medicine in Russia, is being discussed.

Terapevticheskii arkhiv. 2023;95(7):602-606
pages 602-606 views


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies